Robotic Radiotherapy Market

Robotic Radiotherapy Market Size was valued at USD 1.2 Bn in 2023 and is predicted to reach USD 2.9 Bn by 2031 at a 12.0% CAGR during the forecast period for 2024-2031.

Radiosurgery and Radiotherapy Robotics are innovative methods in the field of radiation oncology that utilize robotic systems to deliver precise radiation therapy treatments to patients. These technologies are transforming the way treatments are administered by improving accuracy, efficiency, and patient comfort. The radiosurgery technique involves the precise delivery of highly focused radiation beams to treat tumors or abnormalities in the body.

On the other hand, radiotherapy robotics utilizes robotic systems to administer radiation therapy with exceptional precision. Both of these approaches represent cutting-edge advancements in oncology, providing patients with highly effective and targeted treatments for cancer and other medical conditions. As a result of the advancements in technology, these systems offer reproducibility in patient positioning and the ability to deliver radiation from various directions while synchronizing with the patient's respiration-induced target motion. This technology is now being proposed as a new local treatment option that can be completed in less than one week, showing promising results.

The COVID-19 pandemic has significantly impacted the Robotic Radiotherapy Market. Initially, there was a slowdown in installations and equipment purchases due to disrupted supply chains and budget constraints in healthcare facilities. However, as the pandemic progressed, there was an increased interest in robotic radiotherapy solutions as they minimize human contact and enable remote treatment planning and monitoring, thereby reducing infection risks. It has led to a gradual recovery in the market, with a growing focus on advanced robotic radiotherapy technologies.

Competitive Landscape

Some of the Major Key Players in the Robotic Radiotherapy Market are:

Varian Medical Systems, Inc.
Elekta
Accuray Incorporated
Viewray Technologies, Inc.
Panacea Medical Technologies Pvt. Ltd.
Iba Proton Therapy
Mevion Medical Systems
Hitachi, Ltd.
Sumitomo Heavy Industries, Ltd.
Protom International
Optivus Proton Therapy, Inc.
P-Cure.
Provision Healthcare, Llc
Standard Imaging, Inc.
Brainlab Ag
C-Rad
Raysearch Laboratories.
Dosisoft Sa.
Mim Software, Inc.
Sun Nuclear Corporation
Scandidos Ab
Vision Rt
Civco Radiotherapy
Lap Gmbh Laser Applikationen
Mvision Ai
Linatech, Inc.

Market Segmentation:

The robotics radiotherapy market is segmented by product, technology, application, and end user. By product, the market is segmented into radiotherapy systems, software, 3D cameras (surface guided), and others. By application, the market is segmented into prostate cancer, breast cancer, lung cancer, head and neck cancer, colorectal cancer, and other cancers. By technology, market divided into linear accelerators, stereotactic radiation therapy systems and particle therapy. The end-user segmentation includes hospitals and independent radiotherapy centers.

By Product, The Software Segment Accounted for the Largest Share of the Robotic Radiotherapy Industry during the Forecast Period

The robotic radiotherapy market is segmented based on the product into radiotherapy systems, software, 3D cameras (surface guided), and others. The software segment accounted for the largest global robotic radiotherapy market share in 2023. Due to its crucial role in improving radiation treatments' accuracy, efficacy, and efficiency, the software sector held the highest share of the global robotic radiotherapy market. Sophisticated software programs are necessary to manage patient data, schedule and administer radiation doses precisely, integrate with imaging devices, and enhance therapy results overall. Continuous developments in software technology, such as machine learning and AI-driven algorithms, have also contributed significantly in this market segment's domination.

Lung Cancer Segment Witness Growth at a Rapid Rate

The lung cancer segment is witnessing growth at a rapid rate in the global robotic radiotherapy market due to several factors. Firstly, lung cancer is one of the most prevalent and deadly forms of cancer, driving the demand for advanced treatment options. According to American Cancer Society, lung cancer is predicted to affect 238,340 persons in 2023 (117,550 men and 120,790 women), of whom 127,070 will lose their lives to the illness. Secondly, robotic radiotherapy offers high precision and accuracy in targeting tumors, which is particularly important in lung cancer due to the close proximity of critical structures and the need to minimize damage to healthy tissues. Additionally, technological advancements in imaging and treatment planning have enhanced the effectiveness of robotic radiotherapy for lung cancer, further boosting its adoption and growth in this market segment.

In the Region, the North America Robotics Radiotherapy Market Holds a Significant Revenue Share.

The North American robotics radiotherapy market is estimated to have the highest market growth share in terms of revenue in the near future. This can be attributed to the healthcare infrastructure, acceleration in the adoption of advanced technologies, as well as the presence of major key market players in the region. Additionally, high healthcare expenditure, favorable reimbursement policies, and increasing prevalence of cancer contribute to the market's growth in North America. Factors such as rising geriatric population, increasing cancer cases, and advancements in healthcare infrastructure are also responsible. Furthermore, government initiatives promoting the adoption of robotics in cancer treatment and favorable reimbursement policies are expected to boost the market's growth.

Recent Developments:

In May 2023, Vision RT received approval from the FDA to commercialize its SGRT product, Map RT, in the US.

In June 2023, Ray Research Laboratories launched Ray Station 12A, an advanced treatment radiation planning system.

In February 2022, MIM Software formed a partnership with Genesis Care, one of the largest providers of cancer care services in Australia.